Madrigal Pharmaceuticals (NASDAQ: MDGL) revenue
Madrigal Pharmaceuticals reported revenue of $958.4m for fiscal 2025, 432.1% more than in fiscal 2024 ($180.1m).
Fiscal 2025 is the highest of the 9 fiscal years on record for Madrigal Pharmaceuticals.
Embed this chart
Copy this code into your website or blog. The chart updates with each new annual report.
Revenue by fiscal year
| Fiscal year | Revenue | Change | Operating profit | Operating margin |
|---|---|---|---|---|
| 2025 | $958.4m | +432.1% | −$300.1m | −31.3% |
| 2024 | $180.1m | — | −$497.9m | −276.4% |
| 2023 | $0.0m | — | −$380.5m | — |
| 2022 | $0.0m | — | −$293.6m | — |
| 2021 | $0.0m | — | −$242.5m | — |
| 2020 | $0.0m | — | −$206.7m | — |
| 2019 | $0.0m | — | −$95.0m | — |
| 2018 | $0.0m | — | −$40.7m | — |
| 2017 | $0.0m | — | −$32.1m | — |
The change compares each fiscal year with the one before. Operating margin is operating profit over revenue from the same filing. Figures are in millions of US dollars, except per-share amounts.
Madrigal Pharmaceuticals revenue compared with its sector
By revenue for its latest fiscal year, Madrigal Pharmaceuticals ranks 152nd of the 422 US health care companies with a page on Celsmar. The sector median grew 11.7% in its latest fiscal year; Madrigal Pharmaceuticals, 432.1%.
| Rank | Company | Revenue | Revenue growth |
|---|---|---|---|
| 150th | Guardant Health | $982.0m | 32.9% |
| 151st | Claritev | $965.4m | 3.7% |
| 152nd | Madrigal Pharmaceuticals | $958.4m | 432.1% |
| 153rd | Pennant Group | $947.7m | 36.3% |
| 154th | Ionis Pharmaceuticals | $943.7m | 33.8% |
Each amount is in the currency the company reports in; the rank converts them to US dollars at the 16 November 2026 exchange rate. The rest are in US health care stocks.
Questions about the revenue of Madrigal Pharmaceuticals
- How much revenue did Madrigal Pharmaceuticals make in fiscal 2025?
- Madrigal Pharmaceuticals reported revenue of $958.4m for fiscal 2025, compared with $180.1m in fiscal 2024.
- What was the best year for revenue at Madrigal Pharmaceuticals?
- Of its last 9 fiscal years, fiscal 2025, with $958.4m.
- Where does Madrigal Pharmaceuticals rank in its sector by revenue?
- It ranks 152nd of the 422 US health care companies with a page on Celsmar, by revenue for its latest fiscal year.
- Where do the figures for Madrigal Pharmaceuticals come from?
- From the annual report (Form 10-K) that Madrigal Pharmaceuticals files with the SEC, the US securities regulator. Each fiscal year links to its filing.
Where each figure comes from
From the annual report (Form 10-K) that Madrigal Pharmaceuticals files with the SEC. The filing for each fiscal year: 2025 · 2024 · 2023 · 2022 · 2021 · 2020 · 2019 · 2018 · 2017. More on Madrigal Pharmaceuticals: the Madrigal Pharmaceuticals page · annual accounts · net income · insider transactions.
Information prepared from the accounts the company files with the regulator, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.